All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Dendreon Shares Surge, As Do Others In Cancer Immunotherapy

Nov. 1, 2011
By Aaron Lorenzo
No Comments
If therapeutic cancer vaccine developers were in need of a shot in the arm, they got it last week. Several firms working in the space saw their stock values make measurable gains on Friday, riding the coattails of Dendreon Corp., which Thursday received a positive endorsement from an FDA advisory committee reviewing Provenge (sipuleucel T). (BioWorld Today)
Read More

Budget Analysis: FDA Request Needs More Money, Some Say

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

New WARF Stem Cell Rules To Benefit Biotech Research

Nov. 1, 2011
By Aaron Lorenzo
No Comments
Embryonic stem cell research should advance a bit more freely because of policy changes announced this week by a major patent holder in this area, the Wisconsin Alumni Research Foundation (WARF). The move could clearly benefit biotech companies and possibly negate for now some criticism that the organization has endured. (BioWorld Today)
Read More

In Reworked Deal, Development Costs Now Lie With Cytokinetics

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

NIAID Awards $56.9M R&D Contract To SRI International

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

FDA Gathering Discusses HCV Antiviral Trial Design

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

Genentech's Lucentis Gets FDA Approval For Wet AMD

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

Celgene's Revlimid Gains FDA Approval For Multiple Myeloma

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

Microbia’s $75M Financing To Advance Lead Products

Nov. 1, 2011
By Aaron Lorenzo
No Comments
No Abstract
Read More

Onyx Prices $126M Offering To Pay For Growing Nexavar Costs

Nov. 1, 2011
By Aaron Lorenzo
No Comments
To offset rising expenses related to its lead product, Nexavar (sorafenib tosylate), Onyx Pharmaceuticals Inc. raised about $126 million in gross proceeds through a public placement. (BioWorld Today)
Read More
View All Articles by Aaron Lorenzo

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 13.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing